Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Chemoprevention of Oral Premalignant Lesions

ClinicalTrials.gov ID: NCT00036283

Public ClinicalTrials.gov record NCT00036283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Reduction in size and number of oral premalignant lesions

Study identification

NCT ID
NCT00036283
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
42 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2000 (Type not available)
Primary completion
Not listed
Completion
Apr 2004 (Actual)
Last update posted
Sep 29, 2008

2000 – 2004

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Pfizer Investigational Site Farmington Connecticut 06030-3805 —
Pfizer Investigational Site Shreveport Louisiana 71103 —
Pfizer Investigational Site Ann Arbor Michigan 48109 —
Pfizer Investigational Site Minneapolis Minnesota 55455 —
Pfizer Investigational Site New York New York — —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site Seattle Washington 98195-6607 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00036283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 29, 2008 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00036283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →